China 
Africa 
Explore chapters and articles related to this topic
Menopause And Midlife
Published in Jane M. Ussher, Joan C. Chrisler, Janette Perz, Routledge International Handbook of Women’s Sexual and Reproductive Health, 2019
Most women do not seek medical attention for menopause, but, if they do, it is usually because they have problematic hot flushes and night sweats or they want information and advice (Hickey et al., 2017b). Many women prefer not to take HT, and it is not suitable for some women (e.g., women with a history of breast cancer) (European Menopause and Andropause Society Position Statement [EMAS] 2015; NICE, 2015). Concerns about side effects and safety of HT have contributed to an increased interest in non-hormonal treatments, informed choices for women, and self-management approaches.
Menopause and complementary and integrative medicine
Published in Jon Adams, Amie Steel, Alex Broom, Jane Frawley, Women’s Health and Complementary and Integrative Medicine, 2018
Wenbo Peng, David Sibbritt, Amie Steel, Holger Cramer, Jon Adams
The exclusive menopause guidelines for CIM use are the position statements entitled Nonhormonal Management of Menopause: Associated Vasomotor Symptoms, released by the North American Menopause Society in 2015 (Carpenter et al. 2015) and the EMAS Position Statement: Non-hormonal Management of Menopausal Vasomotor Symptoms, produced by the European Menopause and Andropause Society in 2015 (Mintziori et al. 2015), respectively. The former guidelines recommend cognitive-behavioural therapy and Paroxetine salt for vasomotor symptoms, mindfulness-based stress reduction and soy products for vasomotor symptoms with caution and does not recommend yoga, vitamin supplements, herbal medicines, acupuncture, chiropractic and other CIM for vasomotor symptoms due to insufficient and inconclusive research evidence of their effects. The latter guideline supports these recommendations.
A life devoted to the global care of women
Published in Climacteric, 2023
Manel was the first introducing the contraceptive pill in Portugal in the sixties and in 1967 founded the Portuguese Contraception Society. Moreover, his interest in steroids led him to introduce new hormone measurement methods, which allowed her to start new ovulation stimulation treatments, with human gonadotropins and daily hormonal monitoring of stimulated cycles and in 1975 he created the Portuguese Society of Reproductive Medicine – later affiliated to the International Federation of Fertility Societies. In short, all topics included in the field of reproductive endocrinology was a focus of his interest and menopause was the main target. In 1978 took part in the constitution of the International Menopause Society, being board member until 2006 and one of the promoters of the celebration of the World Menopause Day. In 1995 founded the Portuguese Menopause Society and in 1998 founded with Martin Birkhauser the European Menopause and Andropause Society.
Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review
Published in Climacteric, 2018
A. O. Mueck, X. Ruan, V. Prasauskas, P. Grob, O. Ortmann
Vaginal atrophy is a progressive condition, but a positive vaginal response to therapy is rapid and sustained22. The IMS recommends using an ultra-low dose of vaginal estrogen, although long-term safety clinical data (more than 1 year) are still limited1,23. A consensus on menopausal hormone therapy (MHT) stresses that local, low-dose estrogen therapy should be preferred in women with isolated vaginal dryness and/or associated dyspareunia24. The recommendation is to administer the lowest local dose estrogen therapy in case long-term treatment is required1,23. There is no documented evidence of clinically relevant endometrial effects if ultra-low-dose vaginal estrogen, especially E3, therapy is used. Nevertheless, before initiating the therapy, it is recommended to exclude endometrial pathology. Furthermore, other guidelines by scientific societies such as NAMS, The National Institute for Health and Care Excellence, the European Menopause and Andropause Society, and German S3 are in line with the aforementioned approach25–29.
An extended Menopause Rating Scale II: a retrospective data analysis
Published in Climacteric, 2020
L. Honermann, L. Knabben, S. Weidlinger, N. Bitterlich, P. Stute
Up to 80% of women suffer from climacteric symptoms and up to 42% rate their symptoms as ‘very severe’ with a significant impact on quality of life1,2. Increasing life expectancy leads to a growing group of postmenopausal patients. Maintaining women’s health during and after menopause, last but not least to limit the burden of national economies, is mandatory. Therefore, the European Menopause and Andropause Society published a position statement to optimize health care in postmenopausal patients3. As intensity varies in different women, assessment of symptoms in a standardized manner is essential in order to guide treatment options. Different instruments for the measurement of climacteric symptoms have been developed.